Literature DB >> 7537624

Topography of neovascularity in human prostate carcinoma.

J A Siegal1, E Yu, M K Brawer.   

Abstract

BACKGROUND: All neoplasms require angiogenesis and resulting neovascularity for growth. The authors and others have confirmed the staging and prognostic significance of quantitative microvascularity density (MVD) in human prostate carcinoma (CAP). In the present investigation, the authors sought to identify the specific site of neovascularity within the neoplasm and adjacent benign tissue.
METHODS: Histologically benign and malignant tissues from 14 random radical prostatectomy specimens were studied. The tumor edge was defined precisely by immunohistochemistry, suggesting a high molecular weight cytokeratin that stains only the basal cells of benign histology. Microvascularity density quantification was performed using von Willebrand factor antigen immunohistochemistry as previously defined. Five parallel arcs were defined along which vessel density was calculated including arcs within, on the edge, and removed from the neoplasm.
RESULTS: In 13 of 14 cases, the highest vessel density was found within the tumor. Significant differences were observed between the edge of the tumor and 2.5 mm within the benign periphery, between the benign and malignant tissue at the border, and between CAP at the edge and CAP 2.0 mm within the neoplasm. These findings suggest a stepwise increase in MVD toward the center of the neoplasm.
CONCLUSIONS: These data confirm the authors' previous observation that prostate cancer has approximately a two-fold increase in MVD compared with the benign tissue. Moreover, high vascularization of the center explains the rare finding of necrosis in CAP. These data suggest that angiogenic promoters may have their highest activity in the center of the neoplasm.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7537624     DOI: 10.1002/1097-0142(19950515)75:10<2545::aid-cncr2820751022>3.0.co;2-x

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  26 in total

Review 1.  Prostate cancer prevention: review of target populations, pathological biomarkers, and chemopreventive agents.

Authors:  R Montironi; R Mazzucchelli; J R Marshall; P H Bartels
Journal:  J Clin Pathol       Date:  1999-11       Impact factor: 3.411

2.  Incidental prostatic carcinoma. A predictive role of neoangiogenesis and comparison with other prognostic factors.

Authors:  M Volavsek; A Masera; Z Ovcak
Journal:  Pathol Oncol Res       Date:  2000       Impact factor: 3.201

3.  Imaging prostate cancer invasion with multi-nuclear magnetic resonance methods: the Metabolic Boyden Chamber.

Authors:  U Pilatus; E Ackerstaff; D Artemov; N Mori; R J Gillies; Z M Bhujwalla
Journal:  Neoplasia       Date:  2000 May-Jun       Impact factor: 5.715

Review 4.  Dynamic contrast-enhanced magnetic resonance imaging and pharmacokinetic models in prostate cancer.

Authors:  Tobias Franiel; Bernd Hamm; Hedvig Hricak
Journal:  Eur Radiol       Date:  2010-12-24       Impact factor: 5.315

Review 5.  Overview of dynamic contrast-enhanced MRI in prostate cancer diagnosis and management.

Authors:  Sadhna Verma; Baris Turkbey; Naira Muradyan; Arumugam Rajesh; Francois Cornud; Masoom A Haider; Peter L Choyke; Mukesh Harisinghani
Journal:  AJR Am J Roentgenol       Date:  2012-06       Impact factor: 3.959

6.  Dynamic contrast-enhanced magnetic resonance imaging in prostate cancer clinical trials: potential roles and possible pitfalls.

Authors:  Fiona M Fennessy; Rana R McKay; Clair J Beard; Mary-Ellen Taplin; Clare M Tempany
Journal:  Transl Oncol       Date:  2014-02-01       Impact factor: 4.243

Review 7.  [Ultrasound contrast agents and prostate cancer].

Authors:  F Frauscher; L Pallwein; A Klauser; A P Berger; F Koppelstaetter; J Gradl; M Schurich; J Bektic; G M Pinggera; E J Halpern; W Horninger; G Bartsch; D zur Nedden
Journal:  Radiologe       Date:  2005-06       Impact factor: 0.635

Review 8.  Contrast specific imaging in the detection and localization of prostate cancer.

Authors:  Hessel Wijkstra; Margot H Wink; Jean J M C H de la Rosette
Journal:  World J Urol       Date:  2004-10-05       Impact factor: 4.226

Review 9.  Molecular and genetic prognostic factors of prostate cancer.

Authors:  Arnab Chakravarti; Gary Guotang Zhai
Journal:  World J Urol       Date:  2003-08-09       Impact factor: 4.226

Review 10.  Current status of thalidomide and CC-5013 in the treatment of metastatic prostate cancer.

Authors:  Tristan M Sissung; Silja Thordardottir; Erin R Gardner; William D Figg
Journal:  Anticancer Agents Med Chem       Date:  2009-12       Impact factor: 2.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.